Skip to main content

Anti-Rheumatic Rx

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article

Urate Lowering Therapy During Acute Gout

Jan 26, 2021

Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?

Read Article

Rheumatologists Rank 2nd in Physician Burnout

Jan 26, 2021

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.

The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical

Read Article

Protective Effects of Colchicine in Non-Hospitalized COVID-19

Jan 25, 2021

A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less,

Read Article

Voclosporin FDA Approved for Lupus Nephritis

Jan 24, 2021

On January 22nd, the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis; voclosporin is a calcineurin-inhibitor immunosuppressant indicated for use in combination with a background immunosuppressive therapy. FDA approval was based on data from the pivotal AURORA

Read Article
2 very large UK population studies (millions of pts) show there is no evidence that NSAID use yields harm in those infected with COVID related deaths. There is either no risk (HR 0.96; 0.80, 1.14) or a reduced risk (HR 0.78; 0.64, 0.94) in these studies. https://t.co/gazA83Ogis

Dr. John Cush RheumNow ( View Tweet)

Jan 23, 2021

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jan 22, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

Jan 21, 2021

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 



Recent data suggest that high viral loads are associated with greater risk for COVID-19 complications and death. A combination of two

Read Article

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

Jan 21, 2021

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Read Article
Factors Predictive of SLE Flare After HCQ Taper/Discontinuation The benefits of hydroxychloroquine in lupus are many, but what if you were to withdraw HCQ? Read more: https://t.co/r5iDXBEuQP https://t.co/LImqA9y8Dn
Dr. John Cush RheumNow ( View Tweet)
Jan 21, 2021

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Dr. John Cush RheumNow ( View Tweet)
Jan 20, 2021

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation

MedPage Today
Jan 19, 2021

The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use,  were predictive of flare in patients with SLE who tapered or discontinued treatment

Read Article
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE
Dr. John Cush RheumNow ( View Tweet)
Jan 16, 2021

RheumNow Podcast – Steroids, IVIG & the Vaccine (1.15.2021)

Jan 15, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...

Read Article

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
Hydroxychloroquine Shortage During COVID-19--According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic. https://t.co/h9hrAfv9xo https://t.co/IVSYCueK2h
Dr. John Cush RheumNow ( View Tweet)
Jan 14, 2021

ProDERM Study: IVIG in Dermatomyositis

Jan 13, 2021

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Jan 13, 2021

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.



This oopen-label, observational, cohort study from 275 sites in Japan, included 1355 systemic lupus erythematosus (SLE) patients

Read Article

Hydroxychloroquine Shortage During COVID-19

Jan 12, 2021

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.



Despite public, political and quasi research evidence supporting

Read Article

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
RheumNow Podcast is up! Benlysta safety, HCQ lowers thromboses, HCQ adherence, Telemedicine, Actemra in COVID,, 2021 looking forward and zoomatology! Watch it here>> https://t.co/PtfEUPB1hc or listen to podcast on Apple> https://t.co/FHJv01AAbC or Android>https://t.co/Iylluqqeej

Dr. John Cush RheumNow ( View Tweet)

Jan 10, 2021

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jan 08, 2021

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article

Adherence to Hydroxychloroquine Lowers Lupus Mortality

Jan 07, 2021

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article
Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025). 69% decr in VTE when levels >1068 ng/mL vs <648 ng/mL https://t.co/kis5zry7uH

Dr. John Cush RheumNow ( View Tweet)

Jan 07, 2021
×